10x Genomics, Inc. TXG R2K
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Profit CAGR of 24.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TXG 10x Genomics, Inc. R2K | 28.30 | - | $3.59B | - | -4.49% | -2.98% | 7.57% | 24.59% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 55.82M | 61.21M | - | 71.91M | 42.91M | 71.82M | 105.82M | 115.84M | 125.30M | 114.50M | 114.61M | 131.07M | 134.28M | 146.82M | 153.64M | 141.01M | 153.10M | - | - | 154.88M | 172.91M | 149.00M | 166.03M | 150.84M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.44M | 47.82M | 48.70M | 52.98M | 44.66M |
| Gross Profit | 23.44M | 27.19M | 31.37M | 35.65M | 39.61M | 40.81M | 45.73M | 58.71M | 56.80M | 32.85M | 57.41M | 88.76M | 110.93M | 100.78M | 89.02M | 86.91M | 100.69M | 98.39M | 99.61M | 95.53M | 92.91M | 104.22M | - | - | 105.44M | 125.08M | 100.31M | 113.05M | 106.18M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 153.97M | 135.66M | 132.55M | 132.59M | 123.22M |
| Operating Income | - | - | -14.93M | - | -3.04M | -10.36M | -9.10M | - | -19.88M | -39.42M | -65.25M | -10.22M | -10.33M | -15.88M | -41.73M | -63.12M | -40.00M | -51.99M | -63.36M | -94.80M | -61.50M | -41.74M | - | - | -48.53M | -10.57M | -32.24M | -19.54M | -17.05M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -38.71M | 46.65M | -19.99M | 63.54M | -5.14M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00K | 0 | 0 | 3.00K | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.51M | 37.00M | -28.20M | -15.19M | -12.85M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 852.00K | 2.46M | -733.00K | 1.06M | 623.00K |
| Net Income | -15.69M | -5.92M | -15.35M | -75.52M | -3.64M | -10.88M | -9.60M | -7.13M | -21.14M | -40.17M | -65.85M | -11.55M | -11.05M | -17.17M | -42.41M | -64.46M | -41.91M | -50.75M | -62.41M | -92.99M | -59.95M | -37.90M | - | - | -34.36M | 34.54M | -27.47M | -16.25M | -13.47M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.22 | -0.41 | -0.65 | -0.11 | -0.10 | -0.15 | -0.38 | -0.57 | -0.37 | -0.44 | -0.53 | -0.79 | -0.50 | -0.32 | - | - | -0.28 | 0.28 | -0.22 | -0.13 | -0.10 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 146.31M | 245.89M | 298.85M | - | 516.41M | 618.73M | 610.78M | 642.82M |
| Cost of Revenue | - | - | - | - | - | 120.39M | 209.41M | 196.30M | 198.94M |
| Gross Profit | 60.52M | 117.65M | 184.86M | 240.38M | - | 396.02M | 409.31M | 414.48M | 443.88M |
| Operating Expenses | - | - | - | - | - | 563.97M | 613.66M | 609.04M | 554.77M |
| Operating Income | -18.38M | -110.76M | -30.57M | -534.14M | - | -167.94M | -204.35M | -194.56M | -110.89M |
| EBITDA | - | - | - | - | - | -128.49M | -205.11M | -133.99M | 3.91M |
| Interest Expense | - | - | - | - | - | 476.00K | 33.00K | 4.00K | 0 |
| Pretax Income | - | - | - | - | - | -161.97M | -248.76M | -177.70M | -39.91M |
| Tax Provision | - | - | - | - | - | 4.03M | 6.34M | 4.93M | 3.64M |
| Net Income | -18.76M | -112.48M | -31.25M | -542.73M | - | -166.00M | -255.10M | -182.63M | -43.54M |
| Diluted EPS | - | - | -0.80 | -5.37 | - | -1.46 | -2.18 | -1.52 | -0.35 |
Compounded Sales Growth
| 5 Years: | 7.57% |
| 1 Year: | -2.60% |
Compounded Profit Growth
| 5 Years: | 24.59% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +197.01% |
| 6 Months: | +48.43% |
| 3 Months: | +22.80% |
| 1 Month: | +40.12% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 124.31M | 605.92M | 45.60M | 929.34M | - | 1.03B | 965.14M | 918.64M | 1.04B |
| Current Assets | - | - | - | - | - | - | - | 635.03M | 596.02M | 584.39M | 684.45M |
| Cash & Equivalents | - | 47.86M | 65.08M | 424.17M | - | 663.60M | - | 219.75M | 359.28M | 344.07M | 473.97M |
| Inventory | - | - | - | - | - | - | - | 81.63M | 73.71M | 83.11M | 56.34M |
| Receivables | - | - | - | - | - | - | - | 104.21M | 114.83M | 87.86M | 47.01M |
| Total Liabilities | - | - | 101.05M | 185.84M | 78.14M | 190.27M | - | 223.24M | 224.10M | 208.50M | 245.04M |
| Current Liabilities | - | - | 32.36M | 63.05M | - | 118.13M | - | 130.96M | 127.16M | 117.63M | 153.45M |
| Long Term Debt | - | - | 25.49M | 19.84M | - | 0 | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 95.18M | 95.37M | 82.61M | 84.36M |
| Total Equity | -96.43M | -112.51M | -219.99M | 420.08M | - | 739.07M | - | 805.74M | 741.04M | 710.13M | 796.33M |
| Shares Outstanding | - | - | - | - | - | - | - | 115.20M | 119.10M | 122.29M | 127.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.70M | -76.41M | 34.63M | -217.90M | - | -33.61M | -15.20M | 6.66M | 136.05M |
| Investing Cash Flow | -3.76M | -6.71M | -42.77M | -38.39M | - | -350.89M | 133.49M | -32.63M | -13.44M |
| Financing Cash Flow | 20.58M | 105.37M | 414.59M | 468.91M | - | 15.82M | 13.67M | 10.91M | 6.80M |
| Capital Expenditure | -3.76M | -6.28M | -42.74M | -36.67M | - | -131.66M | -49.52M | -13.39M | -5.93M |
| Free Cash Flow | -14.46M | -82.69M | -8.12M | -254.56M | - | -165.27M | -64.72M | -6.73M | 130.12M |
| Net Change in Cash | - | - | - | - | - | -368.68M | 131.96M | -15.05M | 129.41M |
| Share Buybacks | 80.00K | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 80.4% | 75.2% | 80.4% | - | 76.7% | 66.2% | 67.9% | 69.1% |
| Operating Margin % | - | -75.7% | -12.4% | -178.7% | - | -32.5% | -33.0% | -31.9% | -17.2% |
| Net Margin % | - | -76.9% | -12.7% | -181.6% | - | -32.1% | -41.2% | -29.9% | -6.8% |
| ROE % | 16.7% | 51.1% | -7.4% | -73.4% | - | -20.6% | -34.4% | -25.7% | -5.5% |
| ROCE % | - | -120.5% | -5.6% | -65.8% | - | -18.7% | -24.4% | -24.3% | -12.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 15.18% | 17.74M | $502.16M |
| 2 | ARK Investment Management, LLC | 10.03% | 11.72M | $331.66M |
| 3 | Blackrock Inc. | 8.62% | 10.08M | $285.31M |
| 4 | Vanguard Portfolio Management LLC | 5.91% | 6.91M | $195.67M |
| 5 | Quantinno Capital Management, LP | 4.63% | 5.41M | $153.18M |
| 6 | Vanguard Capital Management LLC | 4.51% | 5.27M | $149.16M |
| 7 | Sumitomo Mitsui Trust Group, Inc. | 4.37% | 5.11M | $144.64M |
| 8 | Amova Asset Management Americas Inc | 4.37% | 5.10M | $144.47M |
| 9 | Goldman Sachs Group Inc | 3.40% | 3.97M | $112.42M |
| 10 | Geode Capital Management, LLC | 2.48% | 2.90M | $82.20M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TXG